Evan Schaeffer argues that the problems brought to light in the silicosis affair are not necessarily typical of other mass-tort litigation over products such as fen-phen or Vioxx, and that corporate defense lawyers can and do succeed in turning back questionable claims in many of these other areas. Ted joins in in the comments section, and a discussion of asbestos and fen-phen ensues.
Silicosis affair -- typical?
![]() |
| Isaac Gorodetski Project Manager, Center for Legal Policy at the Manhattan Institute igorodetski@manhattan-institute.org |
![]() |
| Bridget Carroll Press Officer, Manhattan Institute bcarroll@manhattan-institute.org |



